Chris Horan
Chief Technical Officer Artiva Biotherapeutics
Christopher Horan spent nearly 14 years at Genentech, a member of the Roche Group, where he held several leadership positions across technical operations, including as Senior Vice President, Global Product and Supply Chain Management for Roche in Basel, Switzerland. In that role, he led a 480-person team supplying all of Roche biopharma products worldwide. Mr. Horan joins Artiva from SanBio, where, as Chief Technical Officer (CTO), he led the process development, manufacturing, supply, and quality systems for their mesenchymal stem cell regenerative medicine approach to brain injury in support of a near-term registration in Japan. Previous to SanBio, he was Chief Technical Operations Officer at Dermira, where he led all aspects of pharmaceutical sciences, manufacturing, quality, supply chain, and procurement to launch the company’s first commercial product. He led the effort to prepare Dermira’s IL-13 monoclonal antibody program for Phase 3 trials and commercial filing and had a key role in supporting the company’s successful acquisition by Eli Lilly and Company. Mr. Horan started his career with over a decade of increasing responsibility in technical operations at Merck & Co. He earned a B.E. in engineering from the Stevens Institute of Technology in New Jersey.
Seminars
What’s the development roadmap for the next decade in cell and gene therapies, and how do technologies build on one another rather than compete?
- Lessons learned from autologous CAR-T to inform next generation designs
- Accelerating allogeneic platforms into the clinic as scalable, off-the-shelf solutions
- The integration potential: how today’s allo approaches can feed into tomorrow’s in vivo delivery models
- Patient access: how to make sure patients benefit at each stage of this innovation curve
